|
Timber Pharmaceuticals, Inc. ("Timber", the "Company", "we", "us") is a
clinical-stage biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases. Our
investigational therapies have proven mechanisms-of-action backed by decades of
clinical experience and well-established CMC (chemistry, manufacturing and
control) and safety profiles. We are initially focused on developing
non-systemic treatments for rare dermatologic diseases including congenital
ichthyosis ("CI"), facial angiofibromas ("FAs") in tuberous sclerosis complex
("TSC"), and sclerotic skin diseases. Our lead mid to late-stage programs are
TMB-001 and TMB-002. TMB-003 is our earliest stage program.
|
|